The inhibition of leukocyte migration from the blood stream to the intestine with the integrin antibody vedolizumab is a new column of the treatment of inflammatory bowel diseases. 

Little is known about the impact of vedolizumab on different leukocyte subsets and the dose-response relationship of the drug.
We hypothesize that the targets of vedolizumab differ at high vs. low serum concentrations, which might result in differential efficacy profiles. 
We therefore aim to characterize differential action of vedolizumab on leukocyte subsets in detail by assessing expression, in vitro and in vivo function. 
Our results might lead to a better mechanistic understanding of current clinical anti-adhesion therapies and might thus lay the basis for optimization of existing therapy protocols.  

Weiterführende Informationen erhalten Sie hier.